Posts Tagged ‘atorvastatin’

November 15th, 2011

SATURN Regression Trial: Gorilla Statin and Statin King Battle to a Draw

An epic battle comparing the two most potent statins — the reigning king atorvastatin versus “gorilla statin” rosuvastatin — has ended with a quiet draw. Results of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN) were presented at the AHA on Tuesday and published simultaneously in the New England Journal of Medicine. Stephen Nicholls and colleagues randomized 1039 […]

September 2nd, 2011

Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis Progression

AstraZeneca announced today that its lipid-lowering agent rosuvastatin (Crestor) was not superior to atorvastatin (Lipitor, Pfizer) in reducing the progression of atherosclerosis, as assessed by IVUS. The company announced the top-line results of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN), which is scheduled to be presented at the American Heart Association meeting in November. The […]

August 4th, 2011

Pfizer Wants to Market OTC Atorvastatin (Lipitor)

Pfizer will attempt to gain FDA approval to sell atorvastatin (Lipitor) over-the-counter, according to a report by Peter Loftus in the Wall Street Journal. In the past, the FDA has turned down requests to market other statins over-the-counter. Lipitor is scheduled to go off patent in November, well before an OTC version of the drug […]

November 23rd, 2010

Greek Study Offers Reassurance About Statin Usage in Patients with Abnormal Liver Tests

In the GREACE (Greek Atorvastatin and Coronary Heart Disease Evaluation) study, 1600 patients with coronary heart disease were randomized to atorvastatin or usual care; of these, 437 had moderately abnormal liver tests at baseline, suggesting non-alcoholic fatty liver disease (NAFLD). In a post-hoc analysis of this subset of patients, published in the Lancet, the GREACE Study […]